Animal health company Zoetis is acquiring VitalRADS, a Texas-based network of radiologists that reviews animal imaging, to accelerate its AI diagnostics capabilities.
The deal gives Zoetis access to VitalRADS's database of more than 30 million images, which will train AI models to automate much of the work currently done by technicians.
This is Zoetis's second data-focused acquisition this year and reflects a broader strategy by non-tech companies to buy proven AI capabilities rather than build them from scratch.
What happened
Animal health company Zoetis agreed to acquire Texas-based VitalRADS, which operates a network of radiologists who review animal imaging around the clock. VitalRADS' database of more than 30 million images will be used as training data to build AI models that can automate technicians' workflow.
Why it matters
Non-tech companies need huge amounts of proprietary data to differentiate their AI technology from competitors. Rather than spend years building its own image database and hiring radiologists, Zoetis chose to acquire the capability already in place at VitalRADS—a faster path to integrated AI diagnostics for its animal health customers.
What to watch
This is Zoetis's second data-focused acquisition this year; earlier, it acquired Neogen's animal genomics business for $160 million（約260億円）, gaining a database of genetic testing records from customers across 120 countries. Zoetis did not disclose the VitalRADS purchase price.
Ask the AI about this article →
Zoetis's acquisition of VitalRADS reflects a strategic choice now facing many non-tech companies as they integrate AI into their operations: build or buy. The article illustrates why acquisition often wins: assembling the necessary ingredients—a proprietary database, specialized talent, and proven workflows—from scratch takes time and resources that existing companies have already invested in. VitalRADS brings both the data (more than 30 million images) and the expertise (a network of radiologists) that would take Zoetis considerable time to develop independently. By acquiring the asset, Zoetis accelerates its ability to differentiate its AI-driven diagnostic offerings in animal health.
This deal also fits into a broader pattern within Zoetis this year. The earlier $160 million（約260億円） acquisition of Neogen's animal genomics business followed the same logic: buying a database of genetic testing records from customers across 120 countries rather than rebuilding that knowledge base. Together, the two acquisitions suggest Zoetis is deliberately assembling a portfolio of proprietary datasets and domain expertise—genetic data and now imaging data—that will power its animal diagnostics AI going forward.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
